BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Update
by Teresa Graham · The Cerbat GemBiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 78,258 shares, an increase of 43.4% from the November 30th total of 54,560 shares. Based on an average daily volume of 182,170 shares, the short-interest ratio is presently 0.4 days. Approximately 5.3% of the shares of the stock are short sold. Approximately 5.3% of the shares of the stock are short sold. Based on an average daily volume of 182,170 shares, the short-interest ratio is presently 0.4 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright upped their target price on BiomX to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.00.
View Our Latest Research Report on BiomX
BiomX Trading Down 7.0%
BiomX stock traded down $0.14 during midday trading on Tuesday, reaching $1.86. The company’s stock had a trading volume of 59,440 shares, compared to its average volume of 127,424. The stock’s 50-day simple moving average is $5.43 and its 200-day simple moving average is $8.03. BiomX has a 52-week low of $1.50 and a 52-week high of $22.06.
About BiomX
BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.
The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.